Array BioPharma appoints vp of clinical development
Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.
With more than 17 years" working in the pharmaceutical industry, Dr Bergstrom will lead Array's clinical science and drug safety activities for its growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.
"Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development," said chief executive Robert Conway.
Prior to joining Array, Dr Bergstrom held various roles Hoffmann-La Roche, most recently as clinical science leader in oncology drug development.
Dr Bergstrom studied at the University of Lund in Sweden where he received his MD and PhD.
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform